ATE422885T1 - Cycloalkyläbü kondensierte indole - Google Patents

Cycloalkyläbü kondensierte indole

Info

Publication number
ATE422885T1
ATE422885T1 AT04754553T AT04754553T ATE422885T1 AT E422885 T1 ATE422885 T1 AT E422885T1 AT 04754553 T AT04754553 T AT 04754553T AT 04754553 T AT04754553 T AT 04754553T AT E422885 T1 ATE422885 T1 AT E422885T1
Authority
AT
Austria
Prior art keywords
cycloalkyläbü
indoles
condensed
condensed indoles
compounds
Prior art date
Application number
AT04754553T
Other languages
English (en)
Inventor
Sharon Davis Boggs
John G Catalano
Kristjan S Gudmundsson
Leah D Aurora Richardson
Paul Richard Sebahar
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE422885T1 publication Critical patent/ATE422885T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04754553T 2003-08-26 2004-06-07 Cycloalkyläbü kondensierte indole ATE422885T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49784503P 2003-08-26 2003-08-26

Publications (1)

Publication Number Publication Date
ATE422885T1 true ATE422885T1 (de) 2009-03-15

Family

ID=34272613

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04754553T ATE422885T1 (de) 2003-08-26 2004-06-07 Cycloalkyläbü kondensierte indole

Country Status (7)

Country Link
US (1) US7622494B2 (de)
EP (1) EP1658068B1 (de)
JP (1) JP2007503434A (de)
AT (1) ATE422885T1 (de)
DE (1) DE602004019541D1 (de)
ES (1) ES2320663T3 (de)
WO (1) WO2005023245A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037791A1 (en) * 2003-10-15 2005-04-28 Chiron Corporation Compositions and methods for viral inhibition
WO2006012310A2 (en) * 2004-06-25 2006-02-02 Genzyme Corporation Carbazole derivatives for treating polycystic kidney disease
JP2008520674A (ja) * 2004-11-22 2008-06-19 スミスクライン ビーチャム コーポレーション Ｈｃｖインヒビター
WO2013139929A1 (en) * 2012-03-22 2013-09-26 Ludwig-Maximilians-Universität München Novel means and methods for treating diseases of the central nervous system, metabolic and cardiac diseases and aging
WO2013177241A1 (en) 2012-05-22 2013-11-28 Trustees Of Dartmouth College Method for synthesizing cycloalkanyl(b}indoles, cycloalkanyl(b) benzofurans, cycloalkanyl(b)benzothiophenes, compounds and methods of use
WO2014041125A1 (en) * 2012-09-13 2014-03-20 Baden-Württemberg Stiftung Gmbh Specific inhibitors of protein p21 as therapeutic agents
WO2016196664A1 (en) * 2015-06-01 2016-12-08 Cedars-Sinai Medical Center Methods and use of compounds that bind to rela of nf-kb
US10882821B1 (en) 2017-09-26 2021-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes
WO2020131573A1 (en) * 2018-12-18 2020-06-25 Nuredis, Inc. Compounds for the reduction of the deleterious activity of extended nucleotide repeat containing genes
WO2025231227A1 (en) * 2024-05-03 2025-11-06 Mogling Bio Inc. New compounds for medical use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001043741A1 (en) * 1999-12-16 2001-06-21 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Cytotoxic n-unsubstituted indoles and cyclopent(b)indoles and method of making and using same
US20040009613A1 (en) * 2001-02-16 2004-01-15 Ming-Ming Zhou Methods of identifying modulators of bromodomains
US20030139609A1 (en) * 2001-09-10 2003-07-24 Skibo Edward B. Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles
CA2505130C (en) 2002-11-08 2009-10-06 Glaxo Group Limited Pharmaceutical compositions
US7351733B2 (en) 2003-06-10 2008-04-01 Smithkline Beecham Corporation Tetrahydrocarbazole derivatives and their pharmaceutical use

Also Published As

Publication number Publication date
US7622494B2 (en) 2009-11-24
DE602004019541D1 (de) 2009-04-02
EP1658068B1 (de) 2009-02-18
EP1658068A1 (de) 2006-05-24
WO2005023245A1 (en) 2005-03-17
JP2007503434A (ja) 2007-02-22
ES2320663T3 (es) 2009-05-27
US20060281804A1 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
ATE425965T1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
SE0203713D0 (sv) Novel compounds
WO2006015035A8 (en) Useful compounds for hpv infection
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
EA200702109A1 (ru) Алкинилпирролопиримидины и их применение в качестве ингибиторов hsp90
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
ATE422885T1 (de) Cycloalkyläbü kondensierte indole
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties